• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Bellerophon Therapeutics Inc. (Amendment)

    2/14/24 4:00:25 PM ET
    $BLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BLPH alert in real time by email
    SC 13G/A 1 g111243sc13ga1.htm AMENDMENT NO. 1

     

    Securities and Exchange Commission

    Washington, DC 20549

     

     

    SCHEDULE 13G/A

     

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Bellerophon Therapeutics, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)

     

     

     

    078771300

    (CUSIP Number)

     

     

     

    December 31, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨Rule 13d-1(b)

     

    ýRule 13d-1(c)

     

    ¨Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     Page 1 of 8 Pages 
      

     

    CUSIP No. 078771300

     

    13G/A Page 2 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (b) ý
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    DELAWARE

     

    Number of
    Shares
    BENEFICIALLY
    Owned by
    Each Reporting
    Person with
    5

    Sole Voting Power

     

    0 

    6

    Shared Voting Power

     

    0

    7

    Sole Dispositive Power

     

    0 

    8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0.0%

    12

    type of reporting person

     

    pN 

     

     Page 2 of 8 Pages 
      

     

    CUSIP No. 078771300

     

    13G/A Page 3 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    Tang Capital Management, LLC

     

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (b) ý
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    DELAWARE

     

    Number of
    Shares
    BENEFICIALLY
    Owned by
    Each Reporting
    Person with
    5

    Sole Voting Power

     

    0 

    6

    Shared Voting Power

     

    0

    7

    Sole Dispositive Power

     

    0 

    8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0.0%

    12

    type of reporting person

     

    OO

     

     Page 3 of 8 Pages 
      

     

    CUSIP No. 078771300

     

    13G/A Page 4 of 8 Pages
    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    KEVIN TANG

     

    2 Check the Appropriate Box if a Member of a Group* (a) ¨
    (b) ý
    3

    SEC Use Only

     

    4

    Citizenship or Place of Organization

     

    united states

     

    Number of
    Shares
    BENEFICIALLY
    Owned by
    Each Reporting
    Person with
    5

    Sole Voting Power

     

    0 

    6

    Shared Voting Power

     

    0

    7

    Sole Dispositive Power

     

    0 

    8

    Shared Dispositive Power

     

    0

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    0

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    0.0%

    12

    type of reporting person

     

    IN 

     

     Page 4 of 8 Pages 
      

     

    Item 1(a).Name of Issuer:

     

    Bellerophon Therapeutics, Inc., a Delaware corporation (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    124 Washington Street, Suite 101, Foxborough, MA 02035

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

     

    Item 2(d).Title of Class of Securities:

     

    Common Stock, par value $0.01 per share (the “Common Stock”)

     

    Item 2(e).CUSIP Number: 078771300

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)Amount Beneficially Owned:

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 0 shares of the Issuer’s Common Stock.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Management. Tang Capital Management beneficially owns 0 shares of the Issuer’s Common Stock.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 0 shares of the Issuer’s Common Stock.

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

     Page 5 of 8 Pages 
      

     

    (b)Percent of Class:

     

    Tang Capital Partners 0.0%
    Tang Capital Management 0.0%
    Kevin Tang 0.0%

     

    (c)Number of shares as to which such person has:

     

    (i)sole power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (ii)shared power to vote or to direct the vote:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (iii)sole power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    (iv)shared power to dispose or to direct the disposition of:

     

    Tang Capital Partners 0 shares
    Tang Capital Management 0 shares
    Kevin Tang 0 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

     Page 6 of 8 Pages 
      

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     Page 7 of 8 Pages 
      

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date:   February 14, 2024  
         
         
    TANG CAPITAL PARTNERS, LP  
         
    By:   Tang Capital Management, LLC, its General Partner  
         
         
    By:   /s/ Kevin Tang  
       Kevin Tang, Manager  
         
         
    TANG CAPITAL MANAGEMENT, LLC
         
         
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
         
         
    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 8 of 8 Pages

     

     

    Get the next $BLPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BLPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Puissance Capital Management Lp sold $111,776 worth of shares (1,076,841 units at $0.10), closing all direct ownership in the company (SEC Form 4)

      4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)

      10/16/23 8:51:41 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Amin Naseem

      4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)

      6/9/23 4:12:24 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Fernandes Peter

      4 - Bellerophon Therapeutics, Inc. (0001600132) (Issuer)

      6/9/23 4:12:06 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Bellerophon Therapeutics Inc. (Amendment)

      SC 13G/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)

      2/14/24 4:50:00 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Bellerophon Therapeutics Inc. (Amendment)

      SC 13G/A - Bellerophon Therapeutics, Inc. (0001600132) (Subject)

      2/14/24 4:00:25 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Bellerophon Therapeutics Inc.

      SC 13G - Bellerophon Therapeutics, Inc. (0001600132) (Subject)

      1/26/24 10:46:43 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLPH
    SEC Filings

    See more
    • Bellerophon Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Bellerophon Therapeutics, Inc. (0001600132) (Filer)

      3/4/24 5:25:30 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Bellerophon Therapeutics Inc.

      DEFA14A - Bellerophon Therapeutics, Inc. (0001600132) (Filer)

      2/12/24 3:44:59 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Bellerophon Therapeutics Inc.

      DEFA14A - Bellerophon Therapeutics, Inc. (0001600132) (Filer)

      2/12/24 12:39:17 PM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Bellerophon Provides Clinical Program Update and Reports Second Quarter 2021 Financial Results

      WARREN, N.J., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the second quarter ended June 30, 2021. "We continue to progress our INOpulse® inhaled nitric oxide therapy in multiple areas of significant unmet need," said Fabian Tenenbaum, Chief Executive Officer of Bellerophon. "Our ongoing pivotal Phase 3 REBUILD study for fibrotic interstitial lung disease, or fILD, patients at risk of associated pulmonary hypertension is progressing well and con

      8/5/21 8:30:00 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bellerophon Appoints Naseem Amin, M.D. as Chairman of its Board of Directors

      WARREN, N.J., May 26, 2021 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced the appointment of Naseem Amin, M.D., as Chairman of its Board of Directors, effective immediately. Dr. Amin, who has served as an Independent Director since 2015, will succeed Jonathan Peacock, who is retiring from the Company's Board. "It has been a privilege to work alongside the talented Bellerophon team over the past several years and to guide the Company's evolution into a late-stage development company," said Mr. Peacock. "With a number of

      5/26/21 8:30:00 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

      Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-COPD and PH-SarcoidosisCompany to host conference call and webcast with slides today at 8:30 AM ET WARREN, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced top-line results from its pivotal Phase 3 REBUILD clinical trial evaluating the safety and efficacy of INO

      6/5/23 7:00:00 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bellerophon Therapeutics Announces Last Patient Has Completed Blinded Treatment in Phase 3 REBUILD Study for INOpulse® in Fibrotic Interstitial Lung Disease

      WARREN, N.J., May 11, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that the last patient has completed blinded treatment in the ongoing Phase 3 REBUILD study of INOpulse®, a proprietary pulsatile nitric oxide delivery system, for the treatment of fibrotic interstitial lung disease (fILD). The Company expects to report top-line results from this study in mid-2023. "The successful and timely completion of the blinded treatment phase of our pivotal Phase 3 REBUILD trial represents a key milestone in our INOpulse® de

      5/11/23 8:30:42 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bellerophon Provides Clinical Program Update and Reports Full-Year 2022 Financial Results

      Completed Enrollment in INOpulse® REBUILD Phase 3 trial; Pivotal Top-line Data Expected in Mid-2023Signed License Agreement with Baylor BioSciences to Commercialize INOpulse® in Greater ChinaStrengthened Balance Sheet Through $5 Million Registered Direct Offering with Life Sciences-focused Institutional Investor WARREN, N.J., March 31, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today provided a clinical program update and reported financial results for the year ended December 31, 2022. "We have achieved significant recent pro

      3/31/23 8:30:00 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BLPH
    Financials

    Live finance-specific insights

    See more
    • Bellerophon Announces Top-Line Data from Phase 3 REBUILD Clinical Trial of INOpulse® for Treatment of Fibrotic Interstitial Lung Disease

      Trial did not meet its primary endpoint related to the change in moderate to vigorous physical activity INOpulse® was safe and well-tolerated, consistent with the overall safety profile demonstrated in Phase 2 and other INOpulse® programs in PH-COPD and PH-SarcoidosisCompany to host conference call and webcast with slides today at 8:30 AM ET WARREN, N.J., June 05, 2023 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced top-line results from its pivotal Phase 3 REBUILD clinical trial evaluating the safety and efficacy of INO

      6/5/23 7:00:00 AM ET
      $BLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care